Cardiac remodelling in end stage heart failure: upregulation of matrix metalloproteinase (MMP) irrespective of the underlying disease, and evidence for a direct inhibitory effect of ACE inhibitors on MMP

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Heart

• Publication date

  2002-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1136/heart.88.5.525PMID 12381651PMCID PMC1767416
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Matrix Metalloproteinase Inhibitors: Applications in Oncology

  2004cited by this paper
• Matrix-Dependent Mechanism of Neutrophil-Mediated Release and Activation of Matrix Metalloproteinase 9 in Myocardial Ischemia/Reperfusion

  2001cited by this paper
• Effect of matrix metalloproteinase inhibition on pancreatic cancer invasion and metastasis: an additive strategy for cancer control.

  2000cited by this paper
• Effect of matrix metalloproteinase inhibition on pancreatic cancer invasion and metastasis: an additive strategy for cancer control.

  2000cited by this paper
• Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease.

  2000cited by this paper
• A Matrix Metalloproteinase Induction/Activation System Exists in the Human Left Ventricular Myocardium and Is Upregulated in Heart Failure

  2000cited by this paper
• Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat.

  2000cited by this paper
• Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction.

  2000cited by this paper
• Addition of matrix metalloproteinase inhibition to conventional cytotoxic therapy reduces tumor implantation and prolongs survival in a murine model of human pancreatic cancer.

  2000cited by this paper
• Effectiveness of batimastat, a synthetic inhibitor of matrix metalloproteinases, in neutralizing local tissue damage induced by BaP1, a hemorrhagic metalloproteinase from the venom of the snake bothrops asper.

  2000cited by this paper
• Myocardial matrix degradation and metalloproteinase activation in the failing heart: a potential therapeutic target.

  2000cited by this paper
• Angiotensin-converting enzyme and matrix metalloproteinase inhibition with developing heart failure: comparative effects on left ventricular function and geometry.

  1999cited by this paper
• Matrix metalloproteinase inhibition during the development of congestive heart failure : effects on left ventricular dimensions and function.

  1999cited by this paper
• Altered balance between matrix gelatinases (MMP‐2 and MMP‐9) and their tissue inhibitors in human dilated cardiomyopathy: potential role of MMP‐9 in myosin‐heavy chain degradation

  1999cited by this paper
• Suppression of experimental abdominal aortic aneurysms by systemic treatment with a hydroxamate-based matrix metalloproteinase inhibitor (RS 132908).

  1999cited by this paper
• Recent advances in matrix metalloproteinase inhibitors research.

  1999cited by this paper
• The alveolar space is the site of intense inflammatory and profibrotic reactions in the early phase of acute respiratory distress syndrome.

  1999cited by this paper
• Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure

  1999cited by this paper
• Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: rationale, design, and baseline characteristics of patients in the Losartan Heart Failure Survival Study--ELITE II.

  1999cited by this paper
• Monocyte chemoattractant protein 1 (MCP-1) gene expression in dilated cardiomyopathy.

  1998cited by this paper
• Differential regulation of monocyte matrix metalloproteinase and TIMP-1 production by TNF-alpha, granulocyte-macrophage CSF, and IL-1 beta through prostaglandin-dependent and -independent mechanisms.

  1998cited by this paper
• Regulation of monocyte MMP-9 production by TNF-alpha and a tumour-derived soluble factor (MMPSF).

  1998cited by this paper
• Differential effects of kinins on cardiomyocyte hypertrophy and interstitial collagen matrix in the surviving myocardium after myocardial infarction in the rat.

  1997cited by this paper
• A tenascin knockout with a phenotype

  1997cited by this paper
• Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation.

  1997cited by this paper
• Post-transcriptional regulation of extracellular matrix metalloproteinase in human heart end-stage failure secondary to ischemic cardiomyopathy.

  1996cited by this paper
• Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies.

  1996cited by this paper
• Regulation of matrix metalloproteinases following cellular transformation

  1996cited by this paper
• Collagen network of the myocardium: function, structural remodeling and regulatory mechanisms.

  1994cited by this paper
• Direct extraction and estimation of collagenase(s) activity by zymography in microquantities of rat myocardium and uterus.

  1993cited by this paper
• Captopril inhibits the 72 kDa and 92 kDa matrix metalloproteinases.

  1993cited by this paper
• Matrix metalloproteinase-9 (92 kDa gelatinase/type IV collagenase) from U937 monoblastoid cells: correlation with cellular invasion.

  1993cited by this paper
• Matrix metalloproteinases and their inhibitors in connective tissue remodeling

  1991cited by this paper
• Comparative studies of tissue inhibition by angiotensin converting enzyme inhibitors.

  1989cited by this paper
• A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

  1976cited by this paper
• Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4

  1970cited by this paper

• Cardioprotective Role of Captopril: From Basic to Applied Investigations

  2025cites this paper
• Developments in Extracellular Matrix-Based Angiogenesis Therapy for Ischemic Heart Disease: A Review of Current Strategies, Methodologies and Future Directions

  2025cites this paper
• Diosmin-loaded chitosan nanoparticles mitigate doxorubicin-evoked cardiotoxicity in rats by featuring oxidative imbalance mechanism, NF-κB, and Bcl-2/Bax pathways.

  2025cites this paper
• Transcoronary study of biomarkers in patients with heart failure: Insights into intracardiac production

  2024influential citation
• Review of the Protective Mechanism of Curcumin on Cardiovascular Disease

  2024cites this paper
• THE ROLE OF BIOCHEMICAL MARKERS AND PATIENT-REPORTED OUTCOMES IN PREDICTING COMPOSITE ONE-YEAR ENDPOINT IN ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION.

  2023cites this paper
• Lisinopril prevents bullous pemphigoid induced by dipeptidyl peptidase 4 inhibitors via the Mas receptor pathway

  2023cites this paper
• Angiotensin-Converting Enzyme (ACE) gene polymorphism and arterial blood pressure among the Tawang Monpa of Eastern Himalayan Mountains: Is there a signature of natural selection?

  2023cites this paper
• Feasibility study of intraoperative pericardial fluid biomarkers and length of stay after cardiac surgery

  2023cites this paper
• Silencing RNA for MMPs May Be Utilized for Cardioprotection

  2022cites this paper
• Assessment of Myocardial Diastolic Dysfunction as a Result of Myocardial Infarction and Extracellular Matrix Regulation Disorders in the Context of Mesenchymal Stem Cell Therapy

  2022cites this paper
• Cardioprotective Effect of Gossypin Against Myocardial Ischemic/Reperfusion in Rats via Alteration of Oxidative Stress, Inflammation and Gut Microbiota

  2022cites this paper
• Biotherapeutic-loaded injectable hydrogels as a synergistic strategy to support myocardial repair after myocardial infarction.

  2021cites this paper
• Synergistic actions between angiotensin-converting enzyme inhibitors and statins in atherosclerosis.

  2021cites this paper
• Matrix metalloproteinase-9 as a messenger in the cross talk between obstructive sleep apnea and comorbid systemic hypertension, cardiac remodeling, and ischemic stroke: a literature review

  2020cites this paper
• Extracellular Matrix in Ischemic Heart Disease, Part 4/4: JACC Focus Seminar.

  2020cites this paper
• Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Extracellular Matrix Remodeling during Left Ventricular Diastolic Dysfunction and Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis

  2020cites this paper
• The role of matrix metalloproteinases in the myocardial remodeling

  2020cites this paper
• Correlation between serum matrix metalloproteinase and myocardial fibrosis in heart failure patients with reduced ejection fraction: A retrospective analysis

  2020cites this paper
• Lipid Peroxidation in Atherosclerotic Cardiovascular Diseases

  2020cites this paper
• Perindopril inhibits myocardial apoptosis in mice with acute myocardial infarction through TLR4/NF-κB pathway.

  2019cites this paper
• Targeting metalloproteinases in cardiac remodeling

  2019cites this paper
• Immunoexpression of MMP-8, MMP-9 and TIMP-2 in dilated cardiomyopathy.

  2019cites this paper
• The Extracellular Matrix in Ischemic and Nonischemic Heart Failure.

  2019cites this paper
• Scleroderma: An insight into causes, pathogenesis and treatment strategies.

  2019cites this paper
• Effects of Curcumin Nanoparticles in Isoproterenol-Induced Myocardial Infarction

  2019cites this paper
• Beyond Reperfusion: Acute Ventricular Unloading and Cardioprotection During Myocardial Infarction

  2019cites this paper
• Inhibitor of lysyl oxidase improves cardiac function and the collagen/MMP profile in response to volume overload.

  2018cites this paper
• Ação do extrato etanólico da casca do pequi (Caryocar brasiliense) na cardiotoxicidade crônica induzida por doxorrubicina em ratos

  2017cites this paper
• Endogenous Annexin-A1 Regulates Haematopoietic Stem Cell Mobilisation and Inflammatory Response Post Myocardial Infarction in Mice In Vivo

  2017cites this paper
• Modelling Cardiac Tissue Growth and Remodelling

  2017cites this paper
• Heart failure and role of circulating MMP-2 and MMP-9.

  2017cites this paper
• Dissecting the Role of the Extracellular Matrix in Heart Disease: Lessons from the Drosophila Genetic Model

  2017cites this paper
• Towards comprehensive cardiac repair and regeneration after myocardial infarction: Aspects to consider and proteins to deliver.

  2016cites this paper
• Biomarkers of apoptosis, inflammation, and cardiac extracellular matrix remodelling in the prognosis of heart failure.

  2016cites this paper
• Remote ischaemic conditioning and its effect on maladaptive cardiac remodelling following myocardial infarction

  2016cites this paper
• The effect of captopril on the expression of MMP-9 and the prognosis of neurological function in herpes simplex encephalitis mice

  2016cites this paper
• Metalloproteinases and Their issue Inhibitors in Pressure-Overloaded uman Myocardium During Heart Failure Progression

  2016cites this paper
• Matrix Metalloproteinase-9 Expression in Calcified Human Aortic Valves: A Histopathologic, Immunohistochemical, and Ultrastructural Study

  2016cites this paper
• Clinical characterisation of cardiac involvement in Anderson-Fabry Disease

  2016cites this paper
• Spatiotemporal Delivery of Complementary Proteins for Repair of the Infarcted Myocardium

  2016cites this paper
• Étude de l’effet de l’injection de Cellules Stromales Mésenchymateuses sur un modèle de fibrose colorectale radio-induite chez le rat

  2016cites this paper
• An integrative somatic mutation analysis to identify pathways linked with survival outcomes across 19 cancer types

  2015cites this paper
• Novel Inflammatory Biomarkers in Cardiovascular Therapeutics.

  2015cites this paper
• Soluble ST2 in Ventricular Dysfunction.

  2015cites this paper
• The Effects of the Angiotensin Converting Enzyme Inhibitor Enalapril and the Angiotensin II Type 1 Receptor Blocker Losartan on Fracture Healing in Rats.

  2015cites this paper
• Histological and biochemical outcomes of cardiac pathology in mdx mice with dietary quercetin enrichment

  2015cites this paper
• Matrix metalloproteinases are involved in cardiovascular diseases.

  2014cites this paper
• Pacing-induced cardiomyopathy: pathophysiological insights through matrix metalloproteinases

  2014influential citation
• Mediators of Mast Cells in Bullous Pemphigoid and Dermatitis Herpetiformis

  2014cites this paper
• Management of Fibrosis: The Mesenchymal Stromal Cells Breakthrough

  2014cites this paper
• Inverse relationship between raft LRP1 localization and non-raft ERK1,2/MMP9 activation in idiopathic dilated cardiomyopathy: potential impact in ventricular remodeling.

  2014cites this paper
• Captopril and Lisinopril Only Inhibit Matrix Metalloproteinase‐2 (MMP‐2) Activity at Millimolar Concentrations

  2014cites this paper
• The role of B-cells in heart failure.

  2014cites this paper
• Expression of matrix metalloproteinases, their inhibitors, and lysyl oxidase in myocardial samples from dogs with end-stage systemic and cardiac diseases.

  2013cites this paper
• Serum concentrations of metalloproteinase 2, metalloproteinase 9 and granzyme B in contact eczema patients

  2013cites this paper
• Nanoliposomal minocycline for ocular drug delivery.

  2013cites this paper
• Significance of matrix metalloproteinase-9 inhibition by imidapril for prevention of abdominal aortic aneurysms in angiotensin II type 1 receptor-knockout mice.

  2013cites this paper
• S-Nitrosylation: Specificity, Occupancy, and Interaction with Other Post-Translational Modifications

  2013cites this paper
• Matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1, B⁺ tenascin-C and ED-A⁺ fibronectin in dilated cardiomyopathy: potential impact on disease progression and patients' prognosis.

  2013cites this paper
• Temporal and spatial expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases following myocardial infarction.

  2012cites this paper
• Comprehensive Evaluation of the Effects of Enalapril on Matrix Metalloproteinases Levels in Hypertension

  2012cites this paper
• Epithelial ovarian cancer: A feasible plan for adjunctive treatment using simultaneous acyclovir, ambrisentan, captopril, disulfiram, fluvoxamine-augmented ramelteon, icatibant, imiquimod peritoneal lavage, and plerixafor

  2012cites this paper
• Matrix metalloproteinase-2 and -9 in glioblastoma: a trio of old drugs-captopril, disulfiram and nelfinavir-are inhibitors with potential as adjunctive treatments in glioblastoma.

  2012cites this paper
• A study of matrix metalloproteinases in cancer and atherosclerosis.

  2012cites this paper
• Matrix metallopropteinases in heart failure.

  2012cites this paper
• Physiological regulation of MMPs and tPA/PAI in the arterial wall of rats by noradrenergic tone and angiotensin II

  2012cites this paper
• Functional, structural and molecular investigations into experimental type-1 and type-2 diabetes-induced cardiomyopathy

  2011cites this paper
• Benazepril Inhibits the Formation of Abdominal Aortic Aneurysms in Rabbits

  2011cites this paper
• An immunohistochemical study of feline myocardial fibrosis.

  2011cites this paper
• Pharmacogenetic Associations of MMP9 and MMP12 Variants with Cardiovascular Disease in Patients with Hypertension

  2011cites this paper
• Quantifying the Proteolytic Release of Extracellular Matrix-Sequestered VEGF with a Computational Model

  2010cites this paper
• Mesenchymal stem cells modified with stromal cell-derived factor 1α improve cardiac remodeling via paracrine activation of hepatocyte growth factor in a rat model of myocardial infarction

  2010cites this paper
• Myocardial Proteases and Matrix Remodeling in Acute Myocarditis and Inflammatory Cardiomyopathy

  2010cites this paper
• Changes of matrix metalloproteinase-9 level is associated with left ventricular remodeling following acute myocardial infarction among patients treated with trandolapril, valsartan or both.

  2010cites this paper
• New hypothesis for insulin resistance in hypertension due to receptor cleavage

  2010cites this paper
• Effect of angiotensin-converting enzyme inhibitor on matrix metalloproteinase-9 activity in patients with Kawasaki disease.

  2010cites this paper
• Effects of angiotensin receptor blocker and calcium channel blocker on experimental abdominal aortic aneurysms in a hamster model.

  2010cites this paper
• MMP-9 inhibition by ACE inhibitor reduces oxidized LDL-mediated foam-cell formation.

  2010cites this paper
• Inflammatory cardiomyopathy (DCMi) : pathogenesis and therapy

  2010cites this paper
• Prognostic significance of adipocytokines and extracellular matrix activity in heart failure patients with high B-type natriuretic peptide.

  2009cites this paper
• Differential control of MMP and t-PA/PAI-1 expressions by sympathetic and renin-angiotensin systems in rat left ventricle.

  2009cites this paper
• Pharmacological implications of MMP-9 inhibition by ACE inhibitors.

  2009cites this paper
• Relations of serum MMP-9 and TIMP-1 levels to left ventricular measures and cardiovascular risk factors: a population-based study

  2009cites this paper
• A Role of Matrix Metalloproteinase-8 in Atherosclerosis

  2009cites this paper
• Extracellular matrix metalloproteinase inducer (EMMPRIN) is increased in human left ventricle after acute myocardial infarction.

  2009cites this paper
• MMP roles in the initiation and progression of cardiac remodeling leading to congestive heart failure

  2008cites this paper
• Imidaprilat inhibits matrix metalloproteinase-2 activity in human cardiac fibroblasts induced by interleukin-1beta via NO-dependent pathway.

  2008cites this paper
• Mitochondrial MMP activation, dysfunction and arrhythmogenesis in hyperhomocysteinemia.

  2008cites this paper
• Extracellular matrix remodeling attenuated after experimental postinfarct left ventricular aneurysm repair.

  2008cites this paper
• leiotropic Effects of Atorvastatin in Heart Failure : Role in xidative Stress , Inflammation , Endothelial Function , and xercise Capacity

  2008cites this paper
• Mesenchymal stem cell transplantation attenuates cardiac fibrosis associated with isoproterenol‐induced global heart failure

  2008cites this paper
• Pleiotropic effects of atorvastatin in heart failure: role in oxidative stress, inflammation, endothelial function, and exercise capacity.

  2008cites this paper
• Pathogenesis of aortic valve stenosis: bench to bedside approach.

  2008cites this paper
• Serum levels of the osteoprotegerin, receptor activator of nuclear factor κ-B ligand, metalloproteinase-1 (MMP-1) and tissue inhibitors of MMP-1 levels are increased in men 6 months after acute myocardial infarction

  2008cites this paper
• Captopril attenuates matrix metalloproteinase-2 and -9 in monocrotaline-induced right ventricular hypertrophy in rats.

  2008cites this paper
• [An effect of perindopril on the level of tumor necrosis factor-alpha and matrix metalloproteinase-9 in peripheral blood in the acute period of atherothrombotic ischemic stroke and myocardial infarction].

  2008cites this paper
• Inhibition of matrix metalloproteinase activity by ACE inhibitors prevents left ventricular remodeling in a rat model of heart failure.

  2007cites this paper
• Plasma MMP-2, MMP-9 and N-BNP in long-term survivors following complicated myocardial infarction: relation to cardiac magnetic resonance imaging measures of left ventricular structure and function.

  2007cites this paper
• Molecular mechanism of imidapril for cardiovascular protection via inhibition of MMP-9.

  2007cites this paper